IQ EQ FUND MANAGEMENT IRELAND Ltd Reduces Stock Position in Zoetis Inc. $ZTS

IQ EQ FUND MANAGEMENT IRELAND Ltd lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 56.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,926 shares of the company’s stock after selling 5,104 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Zoetis were worth $574,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Norges Bank purchased a new position in Zoetis during the 2nd quarter valued at $809,491,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after buying an additional 1,995,491 shares during the period. Corient Private Wealth LLC lifted its holdings in Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after buying an additional 1,191,840 shares during the period. Impax Asset Management Group plc boosted its position in Zoetis by 362.6% during the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after acquiring an additional 922,589 shares in the last quarter. Finally, Swedbank AB grew its holdings in shares of Zoetis by 60.4% during the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after acquiring an additional 917,598 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.5%

NYSE:ZTS opened at $127.40 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The firm has a market cap of $56.14 billion, a P/E ratio of 21.45, a P/E/G ratio of 2.20 and a beta of 0.96. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00. The firm has a 50-day simple moving average of $123.96 and a two-hundred day simple moving average of $136.31.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. Zoetis’s payout ratio is 35.69%.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Pelican Bay Capital Management increased its stake and is betting on Zoetis to benefit from the expanding pet care market — a vote of confidence from an institutional investor that can support the stock. Pelican Bay Capital Management Bets on Zoetis (ZTS) to Capitalize on Expanding Pet Care Market
• Positive Sentiment: The board declared a second‑quarter cash dividend of $0.53 per share (annualized yield ~1.7%; ex‑dividend Apr 20, payable Jun 2). The payout supports income investors and signals steady free cash flow. Zoetis Declares Second Quarter 2026 Dividend
• Positive Sentiment: Analyst coverage from Zacks highlights Zoetis as likely to beat upcoming earnings estimates and flags it as a momentum stock — positive near‑term catalyst if results meet expectations. Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?
• Neutral Sentiment: Coverage pieces note the stock’s year‑to‑date underperformance versus the broader market, though analysts remain cautiously bullish — indicating upside is dependent on execution rather than sentiment alone. Do Wall Street Analysts Like Zoetis Stock?
• Neutral Sentiment: Market calendars note Zoetis is projected to report quarterly results this week — an event that could be a catalyst either way depending on beats or guidance. Zoetis (ZTS) Projected to Post Quarterly Earnings on Thursday
• Negative Sentiment: A valuation/analysis piece cautions that Zoetis’ 2026 outlook is tempered by softer pet clinic visits and increased regulatory scrutiny, which could pressure revenue growth and multiples if trends persist. Zoetis (ZTS) Valuation Check As 2026 Outlook Is Tempered On Softer Pet Visits And Regulatory Scrutiny

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ZTS shares. KeyCorp began coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down previously from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Finally, The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $152.45.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.